ABIN3 Antibody
| Code | Size | Price |
|---|
| PSI-5303-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-5303-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
ABIN3 Antibody: LIND, ABIN-3, ABIN3, LIND, TNFAIP3-interacting protein 3, A20-binding inhibitor of NF-kappa-B activation 3
Application Note:
ABIN3 antibody can be used for detection of ABIN3 by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL.
Antibody validated: Western Blot in human samples and Immunohistochemistry in mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples and Immunohistochemistry in mouse samples. All other applications and species not yet tested.
Background:
ABIN3 Antibody: The nuclear factor NF-κB plays key roles in development and immunity. ABIN3 (A20-binding inhibitor of NF-κB activation 3), also known as TNFAIP3-interacting protein 3 (TNIP3), is a novel negative feedback regulator of LPS-induced NF-κB activation. ABIN3 is a 39 kDa protein that negatively regulates NF-κB activation in response to TNF and LPS. ABIN3 is highly expressed in brain, thymus, lymph node, lung and fetal liver, with low expression in kidney, bone marrow. Through its interaction with A20, ABIN3 interferes with TRAF2-mediated transactivation signals and NF-κB inhibition is mediated by the ABIN-homology domain 2. ABIN3 has been found to be induced by Listeria infection and can be slightly downregulated by dexamethasone. Enhanced expression of ABIN3 in monocytes is associated with sepsis. Thus, ABIN3 is an IL-10-induced gene product capable of attenuating NF-κB in human macrophages yet is inoperative in mice and represents a basis for species-specific differences in IL-10 actions. At least four isoforms of ABIN3 are known to exist.
Background References:
- Verstrepen L, Carpentier I, Verhelst K, et al. Abins: A20 binding inhibitors of NFkappaB and apoptosis signaling. Biochem. Pharmacol.2009; 78:105-14.
- Bouwmeester T, Bauch A, Ruffner H, et al. A physical and functional map of the human TNFα/NFkappaB signal transduction pathway. Nat. Cell Biol.2004; 6:97-105.
- Wullaert A, Verstrepen L, Van Huffel S, et al. LIND/Abin-3 is a novel lipopolysaccharide-inducible inhibitor of NFkappaB activation. J. Biol. Chem.2007; 282:81-90.
- Weaver BK, Bohn E, Judd BA, et al. Abin-3: a molecular basis for species divergence in interleukin-10-induced anti-inflammatory actions. Mol. Cell. Biol.2007; 27:4603-16.
Buffer:
ABIN3 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
ABIN3 antibody was raised against a 17 amino acid synthetic peptide near the carboxy terminus of human ABIN3.
The immunogen is located within the last 50 amino acids of ABIN3.
The immunogen is located within the last 50 amino acids of ABIN3.
NCBI Gene ID #:
79931
NCBI Official Name:
TNFAIP3 interacting protein 3
NCBI Official Symbol:
TNIP3
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Protein Accession #:
NP_079149
Protein GI Number:
192807305
Purification:
ABIN3 Antibody is affinity chromatography purified via peptide column.
Research Area:
Innate Immunity
Swissprot #:
Q96KP6
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | ABIN3 Peptide | PSI-5303P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|